Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs AMINO ACIDS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CLINIMIX E 4.25/25 is a sterile, nonpyrogenic, hypertonic solution of amino acids and dextrose used for parenteral nutrition. Dextrose provides a source of calories and is metabolized to carbon dioxide and water, yielding energy. Amino acids provide building blocks for protein synthesis, tissue repair, and maintenance of nitrogen balance.
Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.
Parenteral nutrition for patients requiring caloric and amino acid intake when oral or enteral nutrition is not possible, insufficient, or contraindicated,Off-label: May be used in specific metabolic disorders requiring controlled amino acid and dextrose delivery
Total parenteral nutrition (TPN) for patients unable to ingest or absorb adequate nutrients,Supplementation in metabolic disorders (e.g., urea cycle disorders, maple syrup urine disease),Treatment of negative nitrogen balance due to trauma, burns, or surgery
Intravenous infusion; dose is individualized based on patient's metabolic needs, weight, and clinical status. Typical adult dose: 1-2 L/day of CLINIMIX E 4.25/25 providing 4.25% amino acids and 25% dextrose. Rate of administration should not exceed 4 mg/kg/min of dextrose equivalent.
1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.
Not applicable as a single drug. The components have varied half-lives: amino acids have a plasma half-life of minutes to hours (e.g., alanine ~15 min); dextrose has a half-life of 1.5-2 hours under normal conditions, prolonged in renal impairment or hyperglycemia. Clinical context: in total parenteral nutrition, continuous infusion maintains steady state. No terminal half-life for the mixture.
Variable; endogenous amino acids: 10–30 min for clearance from plasma; administered doses: distribution half-life ~5–10 min, terminal elimination half-life ~15–30 min, reflecting rapid metabolic utilization and renal reabsorption.
Dextrose undergoes glycolysis and oxidation via the citric acid cycle. Amino acids are deaminated and metabolized via ureagenesis and gluconeogenesis.
Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle. Specific pathways exist for each amino acid; excess nitrogen is converted to urea.
The components of CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER are nutrients and electrolytes that are metabolized or excreted via normal physiological pathways. Amino acids are deaminated, with nitrogen excreted primarily as urea in urine (about 90%) and a small amount in feces. Dextrose is metabolized to carbon dioxide and water, with excess exhaled as CO2 (approximately 50-70% of glucose carbon) or excreted in urine if renal threshold exceeded. Electrolytes are excreted renally in proportion to intake and homeostasis. No single excretion route percentage applies to the mixture; for amino acids, renal excretion of metabolites (urea) accounts for >90% of nitrogen elimination.
Renal: >95% as amino acids and metabolites, primarily reabsorbed; <5% unchanged. Fecal/biliary: negligible (<1%).
Amino acids: variable, generally low (0-30%) bound to albumin and other plasma proteins. Dextrose: negligible protein binding. Electrolytes: calcium is ~40-50% bound to albumin and other proteins; magnesium ~30%; phosphate ~10-20%; others minimal. Overall, component-specific.
Minimal for most amino acids (<10%); albumin and globulins bind tryptophan and aromatic amino acids (~80–90% for tryptophan).
Not applicable as a single entity. Amino acids distribute into total body water (~0.5-0.6 L/kg). Dextrose distributes into extracellular fluid (~0.2 L/kg) initially, then intracellularly. Electrolytes distribute according to their physiological compartments. No meaningful Vd for the mixture.
0.4–0.6 L/kg (total body water); reflects equilibration with intracellular and extracellular fluid compartments.
Intravenous: 100% bioavailability as it is administered directly into the bloodstream. Not applicable to oral or other routes.
Oral: ~90–100% (active transport across intestinal mucosa); IV: 100%.
For GFR 30-59 m L/min: reduce volume by 25-50%; monitor electrolytes. For GFR 15-29 m L/min: reduce volume by 50-75%; avoid if severe renal impairment. For GFR <15 m L/min: contraindicated unless on renal replacement therapy; use with caution and adjust electrolytes.
For GFR <30 m L/min: reduce dose to 0.5-1 g/kg/day; monitor serum amino acids and nitrogen balance.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce amino acid dose by 50%; monitor ammonia. Child-Pugh Class C: avoid due to risk of hepatic encephalopathy; alternative nutrition may be needed.
Child-Pugh B or C: avoid standard formulations; use branched-chain amino acid (BCAA)-enriched solutions at 0.8-1.2 g/kg/day.
Dose based on weight (kg) and caloric needs. Typical: 10-15 m L/kg/day initially, titrate to 20-30 m L/kg/day. Maximum dextrose infusion rate: 0.5 g/kg/hr for neonates, 1 g/kg/hr for older children. Use with caution in low birth weight infants.
0.5-2 g/kg/day IV; titrate based on age, growth, and metabolic needs.
Elderly patients often require lower doses due to decreased renal function; start at lower infusion rates (e.g., 1-2 m L/kg/hr). Monitor fluid balance, electrolytes, and renal function closely. Dose adjustment based on GFR is recommended.
Initiate at 0.8 g/kg/day IV, adjust based on renal function and nitrogen balance; monitor for fluid overload.
Not for intravenous infusion unless admixed with appropriate electrolytes and vitamins. Do not administer simultaneously with blood through the same infusion site because of risk of pseudoagglutination. Use with caution in patients with severe hepatic or renal disease.
Patients receiving amino acid infusions should be monitored for metabolic acidosis, hyperammonemia, and renal function impairment. Solutions with electrolytes should not be used in patients with severe electrolyte imbalances.
Monitor fluid balance, electrolyte concentrations, and acid-base status,Risk of hyperglycemia, hyperosmolarity, and metabolic acidosis,Hepatic and renal impairment require dose adjustment,Contains aluminum which may be toxic with prolonged use,Use with caution in patients with heart failure or pulmonary edema
Use with caution in patients with renal impairment, hepatic failure, heart failure, or metabolic acidosis. Monitor serum electrolytes, blood urea nitrogen, and ammonia levels. Avoid rapid infusion to prevent hyperosmolarity and venous thrombosis.
Hypersensitivity to any component,Severe hyperglycemia or diabetes mellitus with ketoacidosis,Severe hepatic or renal failure (unless adjusted),Intracranial or intraspinal hemorrhage,Anuria (for electrolyte-containing formulations)
Hypersensitivity to any component, inborn errors of amino acid metabolism (e.g., phenylketonuria) without specific formula, severe hyperammonemia, anuria, or metabolic acidosis.
Do not administer with any oral food or enteral nutrition unless specifically ordered; interactions depend on individual patient condition. Concomitant use of oral hypoglycemic agents may require dose adjustment due to dextrose content.
No significant food interactions; however, enteral nutrition should be managed to avoid excessive protein intake. Patients with phenylketonuria must avoid phenylalanine-containing amino acid solutions.
CLINIMIX E 4.25/25 contains amino acids, dextrose, electrolytes, and calcium. No teratogenic effects have been reported in animal studies. In first trimester: limited human data, but no evidence of malformations. Second and third trimesters: no known fetal risks. However, hyperglycemia from dextrose may cause fetal macrosomia and neonatal hypoglycemia if maternal glucose control is poor.
Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimester-specific human data; animal studies show no teratogenicity at standard doses.
Components are endogenous substances normally found in breast milk. Dextrose and amino acids are present in milk; no adverse effects expected. M/P ratio not established. Safe to use during breastfeeding when clinically indicated.
Amino acids are normal constituents of breast milk; supplementation likely results in increased maternal levels but endogenous secretion maintains relatively constant milk levels. M/P ratio not established; generally considered compatible with breastfeeding at recommended doses.
Pregnancy increases plasma volume and renal clearance, but dosing adjustments are not typically required. Monitor glucose and electrolyte levels to avoid hyperglycemia or electrolyte imbalances. Use standard parenteral nutrition guidelines with close monitoring.
No specific dose adjustments required for enteral amino acids. For parenteral nutrition, consider increased requirements in third trimester (protein needs up to 1.5 g/kg/day). Adjust based on maternal weight gain, renal function, and metabolic monitoring.
This formulation provides 4.25% amino acids and 25% dextrose with electrolytes and calcium for total parenteral nutrition. Contains sulfite-free preparation; confirm patient's sulfite allergy status. Monitor serum electrolytes, blood glucose, and liver function tests; adjust infusion rate to avoid refeeding syndrome in malnourished patients.
Amino acid infusions should be administered via central line if osmolarity > 900 m Osm/L to prevent thrombophlebitis. Monitor serum ammonia and BUN in patients with hepatic or renal impairment. Use with caution in patients with inborn errors of amino acid metabolism.
This medication is given intravenously to provide nutrition when you cannot eat.,Report any signs of infection at the IV site: redness, swelling, pain, or fever.,You may need regular blood tests to monitor your blood sugar, electrolyte levels, and liver function.,Do not suddenly stop the infusion without consulting your healthcare provider.,Inform your healthcare provider if you have diabetes, as this solution contains dextrose (sugar).
This medication provides essential building blocks for protein synthesis.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Inform your doctor if you have liver or kidney disease.,Do not take other protein supplements unless directed by your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs AMINO ACIDS, answered by our medical review team.
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by CLINIMIX E 4.25/25 is a sterile, nonpyrogenic, hypertonic solution of amino acids and dextrose used for parenteral nutrition. Dextrose provides a source of calories and is metabolized to carbon dioxide and water, yielding energy. Amino acids provide building blocks for protein synthesis, tissue repair, and maintenance of nitrogen balance.. AMINO ACIDS is a Parenteral Nutrition Solution that works by Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER and AMINO ACIDS depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is: Intravenous infusion; dose is individualized based on patient's metabolic needs, weight, and clinical status. Typical adult dose: 1-2 L/day of CLINIMIX E 4.25/25 providing 4.25% amino acids and 25% dextrose. Rate of administration should not exceed 4 mg/kg/min of dextrose equivalent.. The standard adult dose of AMINO ACIDS is: 1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER and AMINO ACIDS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. CLINIMIX E 4.25/25 contains amino acids, dextrose, electrolytes, and calcium. No teratogenic effects have been reported in animal studies. In first trimester: limited human data, b. AMINO ACIDS is classified as Category C. Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.